MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF

Phase 2

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Amyotrophic Lateral Sclerosis

IONSION363

Phase 3

TEVJF40 mg glatiramer acetate

Phase 2

NRSNPlacebo

Phase 2

TEVA40 mg glatiramer acetate

Phase 2

View Full Landscape

Drug Information

Target Indication

Amyotrophic Lateral Sclerosis

Clinical Trial

NCT01777646

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BCLI

BRAINSTORM CELL THERAPEUTICS INC.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

NurOwn® (MSC-NTF cells)Phase 3

Amyotrophic Lateral Sclerosis (ALS)

NurOwn (MSC-NTF cells)Phase 2

Multiple Sclerosis, Chronic Progressive

MSC-NTF cells transplantation (IM)Phase 2

Amyotrophic Lateral Sclerosis

Nurown MSC-NTF cellsPhase 2

Amyotrophic Lateral Sclerosis (ALS)

MSC-NTF cells transplantation (IT)Phase 2

Amyotrophic Lateral Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts